Anaptysbio, Inc. (ANAB) stock forecast and price target
Price $46.25 · data as of November 13, 2026
12-month price target
Gold marker: average target · white marker: today’s price ($46.25)
Analyst ratings
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $3.24 | +804.8% | $137M |
| Next fiscal year ends December 31, 2027 | $4.63 | +42.7% | $165M |
| Next quarter ends December 31, 2026 | $1.05 | −33.2% | $53M |
| Quarter after ends March 31, 2027 | $1.11 | — | $41M |
Consensus of the analysts covering Anaptysbio, updated daily. In the last 30 days 2 estimates were raised and 0 lowered.
Our model vs. Wall Street
Analysts see 88.6% upside over 12 months. Our discounted cash flow model with moderate assumptions puts Anaptysbio’s intrinsic value about 43% below today’s market value, and it scores 2.6 out of 5 on our checks. Price targets follow sentiment; a DCF follows cash. When both point the same way the signal is stronger. Try your own assumptions.
Frequently asked questions
What is the Anaptysbio stock price target?
The average 12-month target from 8 analysts is $87.25, 88.6% above the current price of $46.25 Targets range from $60.00 to $140.00.
Is Anaptysbio a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 5 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Anaptysbio expected to earn?
Analysts expect EPS of $3.24 for the fiscal year ending December 31, 2026 and $4.63 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.